Over the past 15 years, the treatment landscape for first-line metastatic castration-resistant prostate cancer (mCRPC) has undergone significant changes, marked by the approval and investigation of several new therapies. With multiple pharmacological treatments available for first-line mCRPC, network meta-analyses (NMAs) can serve as a valuable resource for evaluating clinical effectiveness that reflects current and local clinical practice.
Recent clinical guidelines emphasize the importance of standardized reporting and evaluation of clinical trial outcomes in response to the rapidly evolving treatment landscape. However, older trials evaluating relevant treatments may lack certain outcome data, posing challenges when comparing them with recent trials designed to meet current guidelines through NMAs. Advanced statistical methods are needed to predict missing values and enable meaningful comparisons between trials.
The Value & Evidence team at EVERSANA (Stefanie Paganelli, Jenna Ellis, Tim Disher and Imtiaz Samjoo) applied the Daniels and Hughes Surrogate Model, recommended by the National Institute for Health and Care Excellence (NICE), to estimate previously unavailable clinical outcome data for integration into NMAs. This approach ensured a comprehensive analysis that included all relevant treatment options.
These NMA results allow clinicians to make well-informed decisions about the effectiveness of various treatment options for patients with mCRPC. Additionally, these results play a pivotal role in developing future models designed to evaluate the cost-effectiveness of these treatments.
For a deeper understanding, you can access the full article here.
Author
As an Associate Manager on the Value & Evidence team at EVERSANA, Stefanie contributes to evidence synthesis projects that support global Health Economics and Outcomes Research (HEOR) initiatives. Since joining EVERSANA in 2021, Stefanie…
Senior Director, Biostatistics
Tim is an experienced analyst and emerging thought leader in the application of Bayesian methods to complex problems. His Vanier Canada Graduate Funded dissertation research focused on the incorporation of multivariate evidence synthesis in…
Jenna is a Manager on the Value & Evidence team at EVERSANA with experience conducting indirect treatment comparisons. Since joining the team in 2022, Jenna has been involved in the development and execution of…
As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling, to support reimbursement…